Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-target CAR-T/TCR-T Immunotherapy for Malignancies
NCT03638206Phase 2Unknown
- Sponsor
- BinDeBio
- Start
- Mar 2018
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in acute lymphoblastic leukemia (ALL), B cell lymphoma, acute myeloid leukemia (AML) and 13 more, sponsored by BinDeBio. Primary endpoint: Number of Participants With Adverse Events at 60 months. Status: unknown.
02
Conditions
acute lymphoblastic leukemia (ALL)B cell lymphomaacute myeloid leukemia (AML)multiple myeloma (MM)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03638206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03638206.